Development of Alzheimer's Disease Biomarkers: From CSF- to Blood-Based Biomarkers

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2022 Apr 23

PMID 35453600

Authors

Sakulrat Mankhong

Sujin Kim

Seongju Lee

Hyo-Bum Kwak

Dong-Ho Park

Kyung-Lim Joa

Ju-Hee Kang

Affiliations

Soon will be listed here.

Abstract

In the 115 years since the discovery of Alzheimer's disease (AD), our knowledge, diagnosis, and therapeutics have significantly improved. Biomarkers are the primary tools for clinical research, diagnostics, and therapeutic monitoring in clinical trials. They provide much insightful information, and while they are not clinically used routinely, they help us to understand the mechanisms of this disease. This review charts the journey of AD biomarker discovery and development from cerebrospinal fluid (CSF) amyloid-beta 1-42 (Aβ42), total tau (T-tau), and phosphorylated tau (p-tau) biomarkers and imaging technologies to the next generation of biomarkers. We also discuss advanced high-sensitivity assay platforms for CSF Aβ42, T-tau, p-tau, and blood analysis. The recently proposed Aβ deposition/tau biomarker/neurodegeneration or neuronal injury (ATN) scheme might facilitate the definition of the biological status underpinning AD and offer a common language among researchers across biochemical biomarkers and imaging. Moreover, we highlight blood-based biomarkers for AD that offer a scalable alternative to CSF biomarkers through cost-saving and reduced invasiveness, and may provide an understanding of disease initiation and development. We discuss different groups of blood-based biomarker candidates, their advantages and limitations, and paths forward, from identification and analysis to clinical validation. The development of valid blood-based biomarkers may facilitate the implementation of future AD therapeutics and diagnostics.

Citing Articles

Electrochemical Technology for the Detection of Tau Proteins as a Biomarker of Alzheimer's Disease in Blood.

Wang J, Lu X, He Y Biosensors (Basel). 2025; 15(2).

PMID: 39996987 PMC: 11853436. DOI: 10.3390/bios15020085.

Distinctive associations between plasma p-tau181 levels and hippocampal subfield volume across the Alzheimer's disease continuum.

Rich A, Oh H bioRxiv. 2025; .

PMID: 39975208 PMC: 11838288. DOI: 10.1101/2025.01.27.635113.

Biofluid biomarkers for Alzheimer's disease: past, present, and future.

An C, Cai H, Ren Z, Fu X, Quan S, Jia L Med Rev (2021). 2024; 4(6):467-491.

PMID: 39664082 PMC: 11629312. DOI: 10.1515/mr-2023-0071.

Mechanisms and Functions of the Cerebral-Cognitive Reserve in Patients with Alzheimer's Disease: A Narrative Review.

Sidenkova A, Litvinenko V, Bazarny V, Rezaikin A, Zakharov A, Baranskaya L Consort Psychiatr. 2024; 5(3):17-29.

PMID: 39526013 PMC: 11542915. DOI: 10.17816/CP15526.

'Selected' Exosomes from Sera of Elderly Severe Obstructive Sleep Apnea Patients and Their Impact on Blood-Brain Barrier Function: A Preliminary Report.

Guillot P, Celle S, Barth N, Roche F, Perek N Int J Mol Sci. 2024; 25(20).

PMID: 39456840 PMC: 11507461. DOI: 10.3390/ijms252011058.

References

Blennow K, Shaw L, Stomrud E, Mattsson N, Toledo J, Buck K . Predicting clinical decline and conversion to Alzheimer's disease or dementia using novel Elecsys Aβ(1-42), pTau and tTau CSF immunoassays. Sci Rep. 2019; 9(1):19024. PMC: 6911086. DOI: 10.1038/s41598-019-54204-z. View

Mapstone M, Cheema A, Fiandaca M, Zhong X, Mhyre T, MacArthur L . Plasma phospholipids identify antecedent memory impairment in older adults. Nat Med. 2014; 20(4):415-8. PMC: 5360460. DOI: 10.1038/nm.3466. View

Verberk I, Thijssen E, Koelewijn J, Mauroo K, Vanbrabant J, de Wilde A . Combination of plasma amyloid beta and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology. Alzheimers Res Ther. 2020; 12(1):118. PMC: 7523295. DOI: 10.1186/s13195-020-00682-7. View

Siedlecki-Wullich D, Catala-Solsona J, Fabregas C, Hernandez I, Clarimon J, Lleo A . Altered microRNAs related to synaptic function as potential plasma biomarkers for Alzheimer's disease. Alzheimers Res Ther. 2019; 11(1):46. PMC: 6521366. DOI: 10.1186/s13195-019-0501-4. View

Zetterberg H . Blood-based biomarkers for Alzheimer's disease-An update. J Neurosci Methods. 2018; 319:2-6. DOI: 10.1016/j.jneumeth.2018.10.025. View

Alawode D, Heslegrave A, Ashton N, Karikari T, Simren J, Montoliu-Gaya L . Transitioning from cerebrospinal fluid to blood tests to facilitate diagnosis and disease monitoring in Alzheimer's disease. J Intern Med. 2021; 290(3):583-601. PMC: 8416781. DOI: 10.1111/joim.13332. View

Peskind E, Griffin W, Akama K, Raskind M, Van Eldik L . Cerebrospinal fluid S100B is elevated in the earlier stages of Alzheimer's disease. Neurochem Int. 2001; 39(5-6):409-13. DOI: 10.1016/s0197-0186(01)00048-1. View

Shen X, Huang Y, Chen S, Guo Y, Tan L, Dong Q . Plasma phosphorylated-tau181 as a predictive biomarker for Alzheimer's amyloid, tau and FDG PET status. Transl Psychiatry. 2021; 11(1):585. PMC: 8590691. DOI: 10.1038/s41398-021-01709-9. View

Preische O, Schultz S, Apel A, Kuhle J, Kaeser S, Barro C . Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease. Nat Med. 2019; 25(2):277-283. PMC: 6367005. DOI: 10.1038/s41591-018-0304-3. View

10.

Blennow K, Mattsson N, Scholl M, Hansson O, Zetterberg H . Amyloid biomarkers in Alzheimer's disease. Trends Pharmacol Sci. 2015; 36(5):297-309. DOI: 10.1016/j.tips.2015.03.002. View

11.

Schindler S, Bollinger J, Ovod V, Mawuenyega K, Li Y, Gordon B . High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis. Neurology. 2019; 93(17):e1647-e1659. PMC: 6946467. DOI: 10.1212/WNL.0000000000008081. View

12.

Hansson O . Biomarkers for neurodegenerative diseases. Nat Med. 2021; 27(6):954-963. DOI: 10.1038/s41591-021-01382-x. View

13.

Agnello L, Piccoli T, Vidali M, Cuffaro L, Lo Sasso B, Iacolino G . Diagnostic accuracy of cerebrospinal fluid biomarkers measured by chemiluminescent enzyme immunoassay for Alzheimer disease diagnosis. Scand J Clin Lab Invest. 2020; 80(4):313-317. DOI: 10.1080/00365513.2020.1740939. View

14.

Jack Jr C, Bennett D, Blennow K, Carrillo M, Dunn B, Budd Haeberlein S . NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018; 14(4):535-562. PMC: 5958625. DOI: 10.1016/j.jalz.2018.02.018. View

15.

Lewczuk P, Ermann N, Andreasson U, Schultheis C, Podhorna J, Spitzer P . Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer's disease. Alzheimers Res Ther. 2018; 10(1):71. PMC: 6064615. DOI: 10.1186/s13195-018-0404-9. View

16.

Zetterberg H, Blennow K . From Cerebrospinal Fluid to Blood: The Third Wave of Fluid Biomarkers for Alzheimer's Disease. J Alzheimers Dis. 2018; 64(s1):S271-S279. DOI: 10.3233/JAD-179926. View

17.

Uhlen M, Fagerberg L, Hallstrom B, Lindskog C, Oksvold P, Mardinoglu A . Proteomics. Tissue-based map of the human proteome. Science. 2015; 347(6220):1260419. DOI: 10.1126/science.1260419. View

18.

Olsson B, Lautner R, Andreasson U, Ohrfelt A, Portelius E, Bjerke M . CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. Lancet Neurol. 2016; 15(7):673-684. DOI: 10.1016/S1474-4422(16)00070-3. View

19.

Fukuyama R, Izumoto T, Fushiki S . The cerebrospinal fluid level of glial fibrillary acidic protein is increased in cerebrospinal fluid from Alzheimer's disease patients and correlates with severity of dementia. Eur Neurol. 2001; 46(1):35-8. DOI: 10.1159/000050753. View

20.

Vergallo A, Megret L, Lista S, Cavedo E, Zetterberg H, Blennow K . Plasma amyloid β 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer's disease. Alzheimers Dement. 2019; 15(6):764-775. DOI: 10.1016/j.jalz.2019.03.009. View